1. home
  2. #tags
  3. European Central Bank

Discover Latest #European Central Bank News, Articles and Videos with Contenting

The European Central Bank (ECB) is the central bank of the European Union, which is responsible for the monetary policy of the Eurozone. The ECB is an independent institution, which works to ensure price stability in the Eurozone, and to promote economic growth and financial stability. The ECB sets the interest rates for the Eurozone, and is responsible for the issuance of the Euro currency. The ECB is headed by a President and is responsible to the European Parliament. The ECB also works in partnership with the national central banks of the Eurozone countries. The ECB has become increasingly influential in recent years, as it has had to take on a greater role in the management of the Eurozone crisis. The ECB publishes regular press releases and holds regular press conferences, to keep the media and public informed about its decisions and activities. The ECB also produces regular economic reports, which provide an overview of the Eurozone economy and monetary policy. The ECB also regularly produces videos and articles about the Eurozone economy and monetary policy. These videos and articles provide an insight into the work of the ECB, and can help to explain the decisions and actions of the ECB.

European Shares Seen Lower; Central Bank Decisions And Trump's Tariff Plans In Focus - ForexTV

European stocks are anticipated to open predominantly lower on Thursday as investors seek further clarity regarding U.S. President Donald Trump's policy agenda.Asian markets displayed mixed trends, with upticks observed in the Chinese and Hong Kong markets. This followed the announcement of medium- and long-term investment plans by several Chinese government departments aimed at bolstering the country's struggling stock market.China has unveiled a strategic initiative to channel hundreds of billions of yuan annually from state-owned insurance companies into the stock market. This move is intended to enhance investor confidence and revitalize the market.The US dollar strengthened in anticipation of a series of central bank decisions expected in the coming week. Concurrently, gold edged down from a near three-month high, whereas oil prices decreased following industry reports indicating the first increase in U.S. crude stockpiles since mid-November.The yen remained relatively stable amid expectations that the Bank of Japan will raise interest rates at the conclusion of its two-day policy meeting on Friday.In terms of economic data releases, attention later in the day may turn to Eurozone consumer confidence survey results, alongside U.S. data on initial jobless claims and the Kansas City Fed manufacturing index.The U.S. stock market experienced gains overnight, propelling Wall Street toward record highs. This surge was supported by strong quarterly results from Netflix, optimism surrounding potential Federal Reserve rate cuts, and President Trump's new initiative focusing on artificial intelligence.The Dow Jones Industrial Average increased by 0.3%, the S&P 500 rose by 0.6%, and the technology-centric Nasdaq Composite advanced by 1.3%.On Wednesday, European stocks broadly rose, with sentiment bolstered by expectations of rate cuts from both the Federal Reserve and the European Central Bank, which countered concerns over Trump's tariff threats.The pan-European STOXX 600 index increased by 0.4%, reaching a nearly four-month high. Germany's DAX index climbed 1% to close at an all-time high, buoyed by Adidas’s strong holiday quarter performance. France's CAC 40 index jumped 0.9%, while the U.K.'s FTSE 100 ended slightly lower.The material has been provided by InstaForex Company - www.instaforex.com

Nxera Pharma Webinar Presentation for FY2024 Financial Results - ForexTV

Tokyo, Japan and Cambridge, UK, 23 January 2025 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2024 on Friday, 14 February 2025. The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, President of Nxera Pharma UK and Head of UK R&D and Makoto Sugita, President of Nxera Pharma Japan and Chief Medical Officer, at 5:00 pm JST (8:00 am GMT) on Friday, 14 February 2025. The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&A session. Please click here to pre-register, which will provide a link to access the webinar. Presentation slides will be made available by 4:30 pm JST (7:30 am GMT) on 14 February 2025 through the investor section of the Company’s Home Page here. – ENDS – About Nxera PharmaNxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsKentaro Tahara, VP Investor Relations and Corporate StrategyShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.